KRYS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

105.97M

+16.27%

1.474

-3.68%

120.26M

+36.37%

1.520

+26.67%

138.92M

+44.64%

1.938

+50.19%

Estimates Revision

The market is revising Upward the revenue expectations for Krystal Biotech, Inc. (KRYS) for FY2025, with the revenue forecasts being adjusted by 1.26% over the past three months. During the same period, the stock price has changed by 38.49%.

Revenue Estimates for FY2025

Revise Upward

+1.26%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+29.92%

In Past 3 Month

Stock Price

Go Up

+38.49%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast KRYS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRYS is 221.00 USD with a low forecast of 198.00 USD and a high forecast of 255.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

198.00

Averages

221.00

High

255.00

Current: 0.000

Low

198.00

Averages

221.00

High

255.00

Clear Street

Buy

upgrade

$217 -> $288

2026-01-09

New

Reason

Clear Street

Price Target

$217 -> $288

2026-01-09

New

upgrade

Buy

Reason

Clear Street raised the firm's price target on Krystal Biotech to $288 from $217 and keeps a Buy rating on the shares. The firm says KB407 successfully induced wild-type CFTR protein expression in patient lung epithelial cells, at levels that are expected to be therapeutically meaningful.

H.C. Wainwright

Buy

maintain

$240 -> $310

2026-01-09

New

Reason

H.C. Wainwright

Price Target

$240 -> $310

2026-01-09

New

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Krystal Biotech to $310 from $240 and keeps a Buy rating on the shares. The KB407 clinical update delivered positive molecular proof-of-concept in cystic fibrosis patients, the analyst tells investors in a research note.

Citi

Buy

maintain

$309 -> $320

2026-01-09

New

Reason

Citi

Price Target

$309 -> $320

2026-01-09

New

maintain

Buy

Reason

Citi raised the firm's price target on Krystal Biotech to $320 from $309 and keeps a Buy rating on the shares. The firm cites the company's positive cystic fibrosis update for the target bump.

BofA

Alec Stranahan

Buy

maintain

$255 -> $272

2026-01-06

New

Reason

BofA

Alec Stranahan

Price Target

$255 -> $272

2026-01-06

New

maintain

Buy

Reason

BofA analyst Alec Stranahan raised the firm's price target on Krystal Biotech to $272 from $255 and keeps a Buy rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its coverage, the analyst tells investors. Over the past few months, several key items "have fallen into place," including positive data catalysts being rewarded; large-cap biopharma spending cash on M&A and in-licensing; growing backlog of companies on the private side; improving access to capital; and limited impact from drug price regulation, BofA says. The firm believes biotech is back, but the biggest concern is whether this will last.

Citi

Neutral -> Buy

upgrade

$198 -> $309

2026-01-06

New

Reason

Citi

Price Target

$198 -> $309

2026-01-06

New

upgrade

Neutral -> Buy

Reason

Citi upgraded Krystal Biotech to Buy from Neutral with a price target of $309, up from $198. The firm sees opportunities in SMID-cap biotech heading into 2026 for commercial or near-commercial stage companies. As part of its 2026 outlook, Citi upgraded both Arvinas and Krystal Biotech while adding an "upside 90-day catalyst watch" on Olema Oncology.

Citi

Yigal Nochomovitz

Neutral

maintain

$166 -> $198

2025-11-04

Reason

Citi

Yigal Nochomovitz

Price Target

$166 -> $198

2025-11-04

maintain

Neutral

Reason

Citi analyst Yigal Nochomovitz raised the firm's price target on Krystal Biotech to $198 from $166 and keeps a Neutral rating on the shares following the Q3 report. Citi views the shares as fairly valued but believes Krystal is well positioned into its 2026 pipeline readouts.

Valuation Metrics

The current forward P/E ratio for Krystal Biotech Inc (KRYS.O) is 34.94, compared to its 5-year average forward P/E of -14.32. For a more detailed relative valuation and DCF analysis to assess Krystal Biotech Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-14.32

Current PE

34.94

Overvalued PE

52.93

Undervalued PE

-81.57

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

13.23

Current EV/EBITDA

26.65

Overvalued EV/EBITDA

59.66

Undervalued EV/EBITDA

-33.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

165.37

Current PS

13.92

Overvalued PS

745.79

Undervalued PS

-415.05

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

KRYS News & Events

Events Timeline

No data

News

9.0

01-08NASDAQ.COM

PinnedKrystal Biotech to Release Interim Clinical Update on KB407 from Highest Dose Cohort of CORAL-1 Study

8.0

21:03 PMNASDAQ.COM

Krystal Biotech (KRYS) Sees Options Trading Volume Surge to 2,445 Contracts

2.0

15:04 PMNASDAQ.COM

Krystal Biotech (KRYS) Stock Rises 32.2%, Indicating Strong Trend

People Also Watch

Frequently Asked Questions

What is Krystal Biotech Inc (KRYS) stock price today?

The current price of KRYS is 261.41 USD — it has increased 5.02 % in the last trading day.

What is Krystal Biotech Inc (KRYS)'s business?

Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.

What is the price predicton of KRYS Stock?

What is Krystal Biotech Inc (KRYS)'s revenue for the last quarter?

Krystal Biotech Inc revenue for the last quarter amounts to 97.80M USD, increased 16.65 % YoY.

What is Krystal Biotech Inc (KRYS)'s earnings per share (EPS) for the last quarter?

Krystal Biotech Inc. EPS for the last quarter amounts to 2.66 USD, increased 192.31 % YoY.

What changes have occurred in the market's expectations for Krystal Biotech Inc (KRYS)'s fundamentals?

How many employees does Krystal Biotech Inc (KRYS). have?

Krystal Biotech Inc (KRYS) has 275 emplpoyees as of January 09 2026.

What is Krystal Biotech Inc (KRYS) market cap?

Today KRYS has the market capitalization of 7.58B USD.